FibroBiologics Inc. Common Stock

FBLG | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.38

+$0.02 (+1.47%)

Sep 22, 2026, 2:30 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.47%

(1D)

Rating

Updated: Sep 2, 2026

18.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.89M

1D Range

1.35 1.41

52W Range

0.62 12.40

Valuation (TTM)

PE -0.21

PB 0.61

EV/EBITDA -0.04

Valuation (NTM)

Forward PE N/A

Forward PEG -0.03

Price Target $180

Cash Flow

FCF Yield -519.1%

SBC Adj. FCF Yield -617.5%

SBC Impact -19.0%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 33.9% | -29.6%

FCF 3Y | 5Y -20.3% | -46.8%

Returns

ROA -228.8%

ROE -536.8%

ROIC -274.3%

Financial Health

Net Cash

$2.18M

Current Ratio 2.64

Interest Coverage -77.81

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline include...

Sector Healthcare

Industry Biotechnology

Employees 15

IPO Date Jan 31, 2024

Website www.fibrobiologics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$180

Upside

+12943.48%

Buy (1)

Hold (2)

Sell (0)

Analyst Details ➞